Archive for the ‘Cancer’ Category
An experimental therapy has brought prolonged remissions to a high proportion of patients who were facing death from advanced leukemia after standard treatments had failed, researchers are reporting.
The therapy involves genetically programming cells from the patient’s own immune system to fight the disease.
The research included 30 patients: five adults ages 26 to 60, and 25 children and young adults ages 5 to 22. All were severely ill, with acute lymphoblastic leukemia, and had relapsed several times or had never responded to typical therapies. In more than half, the disease had come back even after a stem-cell transplant, which usually gives patients the best hope of surviving. Their life expectancy was a few months, or in some cases just weeks.
Six months after being treated, 23 of the 30 patients were still alive, and 19 of them have remained in complete remission.
Estrogen may play a larger role than previously thought in the development of breast cancer.
Scientists from the University of Illinois at Urbana-Champaign discovered that estrogen readies cells to divide, grow and, in some cases, resist breast cancer drugs.
Estrogen has already been known to promote the growth and migration of breast cancer cells.
The researchers’ work, published in the journal Oncogene, could help in the development of new breast cancer treatments and help determine which patients need the most intensive treatment.
Biochemistry professor David Shapiro and his colleagues discovered that estrogen pre-activates a cellular process called the unfolded-protein response (UPR). In healthy cells, the UPR helps cells respond to stress. But in cancerous cells, activating the pathway spurs their division and subsequent expansion, and helps the cancer cells resist anticancer drugs.
A bacterium that is naturally toxic to cattle, sheep, and humans can be tweaked to fight difficult-to-treat cancer tumors.
The modified version of Clostridium novyi bacterium produced strong and precisely targeted results in cancers in rats, dogs, and now a human subject, scientists report.
Before injecting spores into tumors in test subjects, researchers removed one of the bacterium’s toxin-producing genes to make it safer for therapeutic use, though it still caused side effects.
“One advantage of using bacteria to treat cancer is that you can modify these bacteria relatively easily, to equip them with other therapeutic agents, or make them less toxic as we have done here,” says Shibin Zhou, associate professor of oncology at Johns Hopkins Kimmel Cancer Center.
In its natural form, C. novyi is found in the soil and can contaminate open wounds and cause tissue-damaging and potentially fatal infection in grazing animals and humans.
The microbe thrives only in oxygen-poor environments. That makes it suitable for destroying oxygen-starved cells in tumors that are difficult to treat with chemotherapy and radiation; at the same time, it spares nearby healthy, oxygen-rich tissue.
Taking a small daily dose of aspirin can significantly reduce the risk of developing – or dying from – bowel, stomach and oesophageal cancer, according to a large review of scientific studies.
Researchers who analyzed all available evidence from studies and clinical trials assessing benefits and harm found that taking aspirin for 10 years could cut bowel cancer cases by around 35 percent and deaths from the disease by 40 percent.
A 19-year-old Chicago teen may one day hold the key to curing colon cancer.
If his previous successes are any indication, Keven Stonewall is well on his way to becoming the kind of scientist who leaves a lasting impact in the realm of cancer research.
In his senior year of high school, this young man from the city’s South Side was already working on a potential colon cancer vaccine at a Rush University lab, DNAInfo reports.
“My friends, family members have died from cancer,” Stonewall said in a VNM video. “A lot of people are impacted by cancer. So I felt it was my role to step up and do something about it.”
At first, his friends mocked his dedication to science. When they were out on vacation, he was holed up in his lab.
“I was one of the few kids who were engaged,” Stonewall said. “At first they were making fun of me, like ‘Come on man, why you want to be in the lab all day?’”
But after realizing that his lab time was producing real results, his buddies turned around. In fact, they confessed they were inspired by him.
A scorpion-venom concoction that makes tumors glow sounds almost too outlandish to be true. In fact, Olson explains, that’s what troubled the big grant-making organizations when he came to them for funding. But when those organizations dismissed his ideas as too bizarre, Olson started accepting donations from individuals—particularly the families of current and former patients—quickly raising $5 million for his research. It was a bold and unprecedented tactic: Though patients and their families are often asked to donate to foundations with broad goals, Olson raised money for one specific, untested technology—a much riskier gamble. But thanks to his efforts, Olson’s fluorescent scorpion toxin is now in Phase I clinical trials, an impressive accomplishment for a compound with such a peculiar lineage. The University of Washington students are clearly awed by the work.
Olson thought he could accomplish this feat by modifying a molecule known to bind specifically to cancer cells. If he could attach a fluorescent dye to such a molecule, maybe he could make the tumors glow a brilliant blue or green when viewed through a near-infrared camera positioned next to the operating table. Surgeons would then have no problem seeing exactly where a tumor began and ended.
Traditionally, head and neck cancer patients were older men who smoke and drank heavily. The alcohol and tobacco damaged the cells in the throat, eventually leading to cancer.
HPV-caused cancer is different. The men (and it’s still mostly men) who get it are younger. In a series of cases at Mount Sinai, they were between 35 and 65.
Five years ago, I profiled Maura Gillison, the Ohio State University researcher who helped establish that this was a big problem. She told me how when enrolling a study several years ago, she’d recruited, in sequence, a malpractice lawyer, doctor, a scientist and a rear admiral. The first patient I spoke to about his HPV throat cancer was a consultant and economist who later died from his disease. Two years ago, I wrote about a 50-year-old biotech CEO who also had HPV throat cancer. Last year, the actor Michael Douglas said that his throat cancer was caused by HPV.
The point is that these are men much like Dimon: CEOs and consultants, men at the peak of their lives and professional power. And their numbers are increasing.
How do you get HPV cancer? HPV is sexually transmitted. It’s mainly known as a cause of cervical cancer, which is what happens when it infects women. But men can get it by performing cunnilingus. It’s also possible, though less likely, that it can be transmitted by kissing. Eighty percent of sexually active people between the ages of 14 and 44 have had oral sex with an opposite sex partner. Researchers estimate that HPV throat cancer in men will be more common than cervical cancer in women in the U.S.
A highly personalized medical technique is allowing patients with advanced kidney cancer to live nearly three times as long as they normally do. In an experiment involving 21 patients, around half lived more than two and half years after diagnosis with kidney cancer that had begun to spread. Five patients are alive after more than five years.
The findings are part of a large wave of positive results coming from a class of oncology treatments called cancer immunotherapies. Many drug companies, large and small, are working on treatments that instigate the immune system to attack cancer (see “The Revival of Cancer Immunotherapy”). There are a variety of methods for revving up immune cells. In some cases, like the experimental kidney cancer treatment, doctors train a patient’s own white blood cells to spot a cancer cell among its harmless neighbors.
Most so-called cancer vaccines are off-the-shelf products that teach immune cells to attack cancer cells bearing a particular protein. Since cancer is known for its tendency to mutate, these off-the-shelf treatments “may be targeting something that doesn’t exist in each patient,” says Jeff Abbey, CEO of Argos Therapeutics, the Durham, North Carolina, biotech that developed the kidney cancer treatment. Argos is taking a more personalized approach. “We think that the only way to win is to do an active specific immunotherapy that captures all the mutations,” Abbey says.
Owners of a Kentucky cancer clinic will pay $3.7 million to settle claims they prolonged chemotherapy for some of their patients to pad their bills to the government.
The owners of Elizabethtown Hematology Oncology were initially accused by a whistleblower of extending chemo treatments, according to the Louisville Courier-Journal. They were alleged to have submitted false claims for payment to Medicare; Medicaid; Tricare, the military’s medical provider; and the Federal Employee Health Benefit Program over five years beginning in 2010.
Elizabethtown is outside Fort Knox, Ky., and has a substantial military community.
In his lawsuit, whistleblower Dr. Ijaz Mahmood alleged the clinic increased chemotherapy treatment lengths by a factor of three or more beyond the medical standards “in order to inflate billings.”
A study presented at a scientific meeting suggests we are getting closer to having a reliable, non-invasive breath test for lung cancer. Led by the University of Colorado Cancer Center in Denver, the study shows how a device that uses a gold nanoparticle sensor can not only tell whether exhaled breath has come from a patient with COPD or lung cancer, but it can also sense whether the cancer is in early or advanced stages.
The study is the work of Fred R. Hirsch, professor of medical oncology at the University of Colorado School of Medicine, and colleagues, and was presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL.
Prof. Hirsch says a breath test for lung cancer could “totally revolutionize lung cancer screening and diagnosis. The perspective here is the development of a non-traumatic, easy, cheap approach to early detection and differentiation of lung cancer.”